Showing 1,341 - 1,360 results of 27,451 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 50 ((mg decrease) OR (we decrease)) ))', query time: 0.85s Refine Results
  1. 1341
  2. 1342
  3. 1343
  4. 1344
  5. 1345
  6. 1346

    The Reversal Effects of 3-Bromopyruvate on Multidrug Resistance <i>In Vitro</i> and <i>In Vivo</i> Derived from Human Breast MCF-7/ADR Cells by Long Wu (655081)

    Published 2014
    “…Multidrug resistance reversal by 3-Bromopyruvate occurred through at least three approaches, namely, a decrease in the intracellular level of ATP and HK-II bioactivity, the inhibition of ATPase activity, and the slight decrease in P-glycoprotein expression in MCF-7/ADR cells.…”
  7. 1347
  8. 1348
  9. 1349
  10. 1350
  11. 1351

    Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  12. 1352

    Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  13. 1353

    Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  14. 1354

    Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  15. 1355

    Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions by Paz Sobrino-Vegas (680195)

    Published 2014
    “…<div><p>Objectives</p><p>We aim to describe rates and risk factors of Hepatitis C Virus (HCV) diagnoses, follow-up HCV testing and HCV seroconversion from 2004–2011 in a cohort of HIV-positive persons in Spain.…”
  16. 1356
  17. 1357
  18. 1358
  19. 1359

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
  20. 1360

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”